Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic analog of growth hormone-releasing hormone (GHRH) that is FDA-approved for HIV-associated lipodystrophy. One of the few peptides with a clear FDA-approved indication, making it a useful reference point for the broader GHRH analog class.
A selective growth hormone secretagogue that stimulates GH release with minimal effects on cortisol and prolactin. Considered one of the 'cleanest' GH-releasing peptides due to its selectivity.
Binds to GHRH receptors on the pituitary gland, stimulating pulsatile GH release. Reduces visceral adipose tissue (VAT) through GH-mediated lipolysis. Maintains the natural pulsatile pattern of GH secretion, preserving feedback mechanisms.
Binds to ghrelin receptors (GHS-R) in the pituitary gland, triggering pulsatile growth hormone release. Unlike other GH secretagogues, it does not significantly increase cortisol, ACTH, or prolactin levels.
- HIV-associated lipodystrophy (FDA-approved)
- Visceral fat reduction
- Metabolic health improvement
- Growth hormone optimization (off-label)
- Cognitive function (emerging research in older adults)
- Growth hormone optimization
- Improved sleep quality
- Fat loss
- Muscle recovery and growth
- Anti-aging protocols
- Injection site reactions (common)
- Fluid retention and edema
- Arthralgia (joint pain)
- Potential glucose metabolism effects
- Contraindicated in active malignancy
- Headaches
- Water retention
- Tingling sensations
- Limited long-term human data
- May affect blood sugar
FDA-approved as Egrifta (tesamorelin for injection) in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Also available through compounding pharmacies for off-label use with a physician prescription.
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
- Ipamorelin, a new growth-hormone-releasing peptide
1998 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.